Skip to main content
IMS Events Main banner
    22nd International Myeloma Society Annual Meeting
    Oral Abstract

    Abstract Session 1

    Wednesday, September 17, 2025
    11:00 - 11:50 East Coast USA Time
    Location: Room 701

    Presentations:

    • 11:00 - 11:10 East Coast USA Time
      (OA-13) Post-Induction Outcomes and Updated Minimal Residual Disease Analysis from GMMG-HD10/DSMM-XX (MajesTEC-5): A Study of Teclistamab-Based Induction Regimens in Newly Diagnosed Multiple Myeloma (NDMM)

      Abstract Presenter: Marc S. Raab, MD PhD (he/him/his) – Dept. of Medicine V Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany

    • 11:10 - 11:20 East Coast USA Time
      (OA-14) Cevostamab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM): Phase I Dose-Expansion Results from the CAMMA 1 Study

      Abstract Presenter: Hira Mian, MD (she/her/hers) – McMaster University, Hamilton, ON, Canada

    • 11:20 - 11:30 East Coast USA Time
      (OA-07) Elranatamab in Combination With Daratumumab and Lenalidomide (EDR) in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant: Initial Results from MagnetisMM-6 Part 1

      Abstract Presenter: Suzanne Trudel, MD – Princess Margaret Cancer Centre, Toronto, ON, Canada

    • 11:30 - 11:40 East Coast USA Time
      (OA-02) Sustained Remission After Limited-Duration of Bispecific Antibody Therapy in Patients with Relapsed/Refractory Multiple Myeloma

      Abstract Presenter: Meera Mohan, MD – Medical College of Wisconsin

    • 11:40 - 11:50 East Coast USA Time
      (OA-35) TRIgnite- 1Study, Phase 1, First-in-Human Study of ISB 2001: A BCMAxCD38xCD3-Targeting Trispecific Antibody for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)—Dose Escalation (DE) Results

      Abstract Presenter: Hang Quach, MBBS(Hons) FRACP FRCPA MD (she/her/hers) – St Vincent’s Hospital Melbourne, University of Melbourne, VIC, Australia